LIGNAN DERIVATIVES POTENTIAL AS PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE INHIBITORS: MOLECULAR DOCKING APPROACH OF ANTIPLASMODIAL DRUG DESIGN
Objectives: To investigate the lignan derivatives potential as Plasmodium falciparum Lactate Dehydrogenase (PfLDH) inhibitors by using Computer Aided Drug Design (CADD) and molecular docking approach.
Methods: In finding potential antiplasmodial, in silico approach has been utilized. Protein structure of PfLDH has been built through homology modeling. Kobamin has been used to refine the 3D PfLDH structure. Structure validation of PfLDH was done by Ramachandran Plot and ERRAT calculations. The validated PfLDH was ready for molecular docking analysis. lignan derivatives as lead compounds were designed. The pharmacophore of lignan derivatives were assessed by using Molsoft drug likeness. Both protein and Lignan derivatives were docked with Autodock Vina. The best docking score was shown by the lowest affinity energy.
Results: Homology modeling of PfLDH has been built. Moreover, PfLDH refinement and validation were importantly conducted to ensure that PfLDH structure was in good quality. According to Ramachandran Plot and Procheck analysis, PfLDH has good structure quality with 93.39% confidence value. On the other hand, lignan derivatives assessment also has been done by evaluating their physicochemical and pharmacophore properties as lead compounds. From this assessment, it showed that Aristoligol (ARG1), Aristoligone (ARG2), and Ester Asetil Aristoligol (ARG3) showed good compounds to be drug likeness by following Lipinskiâ€™s rule of five (RO5), while Ester Butiril Aristoligol (ARG4) showed poor RO5 criteria. Bioavailability of four compounds was good in body metabolism, however, ARG3 and ARG4 could not be lead like compounds due to poor lead likeness value. From molecular docking result, the most favorable binding with PfLDH was ARG4 based on its affinity energy value (-8.0 kj/mol), followed by ARG3, ARG2 and ARG1, respectively.
Conclusions: The identification of potential anti plasmodial drugs was successfully accomplished by evaluating synthetic lignan derivatives compound through physicochemical properties and molecular docking analysis. Overall, physicochemical and pharmacophore properties showed good result. Molecular docking interaction has distinct mode interactions of lignan derivatives with PfLDH. We believe that these evaluated compounds could be used as anti plasmodial drugs according to in silico evaluation results.
2. Burrows JN. Designing the next generation of medicines for malaria control and eradication. Malar J 2013;12:187.
3. Breman JG, AD Brandling-Bennett. The challenge of malaria eradication in the twenty-first century: research linked to operations is the key. Vaccine 2011;29 Suppl 4:D97-103.
4. Malaria: control vs elimination vs eradication. Lancet 2011;378:1117.
5. Harikishore A. Small molecule plasmodium FKBP35 inhibitor as a potential antimalaria agent. Sci Rep 2013;3:2501.
6. Rai R. Genome-wide analysis in Plasmodium falciparum reveals early and late phases of RNA polymerase II occupancy during the infectious cycle. BMC Genomics 2014;15:959.
7. Mbengue A. Novel plasmodium falciparum maurer's clefts protein families implicated in the release of infectious merozoites. Mol Microbiol 2013;88:425-42.
8. Ouedraogo AL. Substantial contribution of submicroscopical plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 2009;4:e8410.
9. Penna-Coutinho J. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS One 2011;6:e21237.
10. Kaushal DC, NA Kaushal. Diagnosis of malaria by detection of plasmodial lactate dehydrogenase with an immunodot enzyme assay. Immunol Invest 2002;31:93-106.
11. Kaushal NA, DC Kaushal. Production and characterization of monoclonal antibodies against substrate specific loop region of Plasmodium falciparum lactate dehydrogenase. Immunol Invest 2014;43:556-71.
12. Bouyou-Akotet MK. Impact of plasmodium falciparum infection on the frequency of moderate to severe anaemia in children below 10 y of age in gabon. Malar J 2009;8:166.
13. Kochar DK. A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India. J Vector Borne Dis 2014;51:200-10.
14. Sulaiman H. Severe plasmodium falciparum infection mimicking acute myocardial infarction. Malar J 2014;13:341.
15. Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC Drug Service. MMWR Recomm Rep 1991;40:21-3.
16. Keluskar P. Plasmodium falciparum and plasmodium vivax specific lactate dehydrogenase: genetic polymorphism study from Indian isolates. Infect Genet Evol 2014;26:313-22.
17. Granchi C. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 2010;17:672-97.
18. Megnassan E. Design of novel dihydroxynaphthoic acid inhibitors of Plasmodium falciparum lactate dehydrogenase. Med Chem 2012;8:970-84.
19. Choi SR. Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J Med Chem 2007;50:3841-50.
20. Choi SR. Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase. J Comb Chem 2007;9:292-300.
21. Conners R. Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase. Mol Biochem Parasitol 2005;142:137-48.
22. Deck LM. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite plasmodium falciparum. J Med Chem 1998;41:3879-87.
23. de Andrade-Neto VF. Antiplasmodial activity of aryltetralone lignans from Holostylis reniformis. Antimicrob Agents Chemother 2007;51:2346-50.
24. Vyas VK. Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonists based on predictive 3D QSAR models. SAR QSAR Environ Res 2014;25:117-46.
25. Zhang Y. De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction. Mol Divers 2012;16:787-802.
26. Nogara PA. Virtual screening of acetylcholinesterase inhibitors using the Lipinski's rule of five and ZINC databank. Biomed Res Int 2015;1-8. doi: 10.1155/2015/870389. [Article in Press]
27. UniProt: a hub for protein information. Nucleic Acids Res 2015;43:D204-12.
28. Alpi E. Analysis of the tryptic search space in UniProt databases. Proteomics 2015;15:48-57.
29. Biasini M. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014;42:W252-8.
30. Bordoli L. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 2009;4:1-13.
31. Arnold K. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006;22:195-201.
32. Schwede T. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381-5.
33. Laskowski RA. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 1996;8:477-86.
34. Carugo O, K Djinovic-Carugo. A proteomic ramachandran plot (PRplot). Amino Acids 2013;44:781-90.
35. Gopalakrishnan K. Ramachandran plot on the web (2.0). Protein Pept Lett 2007;14:669-71.
36. Ho BK, A Thomas, R Brasseur. Revisiting the ramachandran plot: hard-sphere repulsion, electrostatics, and H-bonding in the alpha-helix. Protein Sci 2003;12:2508-22.
37. Kolaskar AS, S Sawant. Prediction of conformational states of amino acids using a ramachandran plot. Int J Pept Protein Res 1996;47:110-6.
38. Colovos C, TO Yeates. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 1993;2;1511-9.
39. Cousins KR. Computer review of chem draw Ultra 12.0. J Am Chem Soc 2011;133:8388.
40. Li Z. Personal experience with four kinds of chemical structure drawing software: review on chem draw, Chem Window, ISIS/Draw, and Chem Sketch. J Chem Inf Comput Sci 2004;44:1886-90.
41. Southan C, A Stracz. Extracting and connecting chemical structures from text sources using chemicalize. org. J Cheminf 2013;5:20.
42. Fernandez-Recio J, M Totrov, R Abagyan. Screened charge electrostatic model in protein-protein docking simulations. Pac Symp Biocomput 2002;552-63.
43. Trott O, AJ Olson. Auto dock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-61.
44. Martel S. Large, chemically diverse dataset of logP measurements for benchmarking studies. Eur J Pharm Sci 2013;48:21-9.
45. Korinth G. Potential of the octanol-water partition coefficient (logP) to predict the dermal penetration behaviour of amphiphilic compounds in aqueous solutions. Toxicol Lett 2012;215:49-53.
46. Smith RN. The general problem of drug bioavailability and its assessment in man. Postgrad Med J 1974;50:7-14.
47. Savjani KT, AK Gajjar, JK Savjani. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012: doi: 10.5402/2012/195727. [Article in Press]
48. Widanapathirana LS Tale, TM Reineke. Dissolution and solubility enhancement of the highly lipophilic drug phenytoin via interaction with poly(N-isopropylacrylamide-co-vinylpyrrolidone) excipients. Mol Pharm 2015;12:2537-43.
49. Docherty R, K Pencheva, YA Abramov. Low solubility in drug development: de-convoluting the relative importance of solvation and crystal packing. J Pharm Pharmacol 2015;67:847-56.